Riskpilot← Back to searchSign inGet full accessHixaDerm AB
ABActiveOrg 5592407893Brännmästaregatan 16Other education n.e.c. · NACE 8559Est. 20201 employees
Revenue 2025
SEK 274K
+5% vs 2024
EBITDA margin
96.5%
+5% vs 2024
Equity ratio
72.3%
Financial strength
Net profit 2025
SEK 210K
+4% vs 2024
| Revenue | SEK 274K | +5% |
| EBITDA | SEK 264K | +5% |
| Net profit | SEK 210K | +4% |
| Total assets | SEK 359K | +10% |
| Equity | SEK 259K | +13% |
| Employees | 1 | — |
Legal name
HixaDerm AB
Org number
5592407893
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
5 februari 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Specialistläkartjänster huvudsakligen inom hud- och könssjukvård. Utbildning inom hälso- och sjukvård, huvudsakligen inom hud- och könssjukvård. Medicinsk rådgivning inom hälso- och sjukvård, huvudsakligen inom hud- och könssjukvård.
Address
Brännmästaregatan 16
Email
sam.polesie@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 218 | 253 | 255 | 261 | 274 |
| Staff expenses | — | −4 | −3 | 1 | −0 |
| EBITDA | 157 | 219 | 226 | 252 | 264 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 157 | 219 | 226 | 252 | 264 |
| Net financials | — | 0 | 3 | 3 | 0 |
| Profit before tax | 156 | 219 | 230 | 255 | 265 |
| Tax | −32 | −45 | −47 | −52 | −54 |
| Net profit | 124 | 174 | 182 | 203 | 210 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 287 | 371 | 367 | 326 | 359 |
| Equity | 220 | 294 | 297 | 229 | 259 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 67 | 77 | 70 | 97 | 99 |
| Total debt | 67 | 77 | 70 | 97 | 99 |
EBITDA margin
96.5%
This company
15.8%
Market median
+511% vs market
20212025
Equity ratio
72.3%
This company
38.2%
Market median
+89% vs market
20212025
Return on equity
81.1%
This company
18.4%
Market median
+341% vs market
20212025
Net profit margin
76.7%
This company
8.1%
Market median
+847% vs market
20212025
Asset turnover
0.76×
This company
1.12×
Market median
-32% vs market
20212025
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HixaDerm AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Linnéa Katarina Larsson | Deputy Board Member | 0 companies |
| Sam Erik Polesie | Board of Directors | 0 companies |